Page 4 - கால்குட்டா பள்ளி ஆஃப் வெப்பமண்டல மருந்து News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from கால்குட்டா பள்ளி ஆஃப் வெப்பமண்டல மருந்து. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In கால்குட்டா பள்ளி ஆஃப் வெப்பமண்டல மருந்து Today - Breaking & Trending Today

Coronavirus outbreak: Vaccine at 10 private hospitals in Kolkata

Coronavirus outbreak: Vaccine at 10 private hospitals in Kolkata
telegraphindia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from telegraphindia.com Daily Mail and Mail on Sunday newspapers.

Uttar Pradesh , West Bengal , Garden Reach , Belle Vue , Apollo Gleneagles , Aurobinda Seva Kendra , Chittaranjan Seva Sadan , Aarogya Setu , Calcutta National Medical College , Rg Kar Medical College , Calcutta School Of Tropical Medicine , Calcutta Medical College , Serum Institute Of India , Diabetes Institute , Medica Hospital , Ruby Hospital , Sri Aurobinda Seva Kendra , Medical College , Vidyasagar State General Hospital , Garden Reach State General Hospital , Lady Dufferin Victoria Hospital , Sambhunath Pandit Hospital , Chittaranjan Seva Sadan Hospital , Calcutta School , Serum Institute , உத்தர் பிரதேஷ் ,

Coronavirus outbreak: Beneficiaries cannot choose between AstraZeneca-Oxford and Bharat Biotech vaccine initially

India’s Covid-19 vaccination campaign starting on January 16 with the AstraZeneca-Oxford vaccine and the homegrown Bharat Biotech jab will not offer beneficiaries the option to choose between the two, the Union health ministry has signalled.
But online discussions and free-wheeling exchanges in medical circles across the country, doctors say, appear to reflect expectations among many that they would receive the AstraZeneca-Oxford vaccine called Covishield in India instead of the homegrown Covaxin.
The health ministry said on Tuesday that 11 million doses of Covishield and 5.5 million doses of Covaxin ordered by the Centre to start the campaign would be received by all states and Union Territories by January 14, but did not explain which vaccine would go where. ....

West Bengal , New Delhi , Vinod Paul , Sumit Ray , Santanu Tripathi , Rajesh Bhushan , Union Territories , Calcutta School Of Tropical Medicine , Serum Institute Of India , Bharat Biotech , Niti Aayog , Holy Family Hospital , Calcutta School , Serum Institute , மேற்கு பெங்கல் , புதியது டெல்ஹி , வினோத் பால் , சுமிட் ராய் , சந்தனு திரிபாதி , ராஜேஷ் பூஷன் , தொழிற்சங்கம் பிரதேசங்கள் , கால்குட்டா பள்ளி ஆஃப் வெப்பமண்டல மருந்து , சீரம் நிறுவனம் ஆஃப் இந்தியா , பாரத் பயோடெக் , நீதி ஆயோக் , பரிசுத்த குடும்பம் மருத்துவமனை ,

India-made Covaxin jumps direct evidence - Telegraph India

India’s drug regulatory expert panel on Saturday recommended conditional and restricted emergency use of a home-grown vaccine against the coronavirus disease without direct evidence for its protective efficacy.
Earlier on Friday, the AstraZeneca-Oxford vaccine had been recommended. The recommendations from the Subject Expert Committee (SEC) to the Central Drugs Standard Control Organisation, the apex regulatory authority for drugs and vaccines, imply India could use two vaccines for its planned campaign to initially vaccinate around 300 million people.
The Union health ministry said on Saturday the SEC had granted the permissions under multiple conditions, but some medical experts said the committee appeared to have yielded to a desire to launch an Indian-made vaccine alongside a foreign one. ....

United Kingdom , West Bengal , Santanu Tripathi , Serum Institute , Calcutta School Of Tropical Medicine , Indian Council Of Medical Research , Expert Committee , Serum Institute Of India , Central Drugs Standard Control Organisation , Subject Expert Committee , Pune Based Serum Institute , Hyderabad Based Bharat Biotech , Indian Council , Medical Research , Calcutta School , Tropical Medicine , Bharat Biotech , ஒன்றுபட்டது கிஂக்டம் , மேற்கு பெங்கல் , சந்தனு திரிபாதி , சீரம் நிறுவனம் , கால்குட்டா பள்ளி ஆஃப் வெப்பமண்டல மருந்து , இந்தியன் சபை ஆஃப் மருத்துவ ஆராய்ச்சி , நிபுணர் குழு , சீரம் நிறுவனம் ஆஃப் இந்தியா , மைய மருந்துகள் தரநிலை கட்டுப்பாடு ஆர்கநைஸேஶந் ,

Serum Institute Fracas Exposes Loose Ends of India's Clinical Trial Machinery

Serum Institute Fracas Exposes Loose Ends of India s Clinical Trial Machinery
Participants voices are missing from deliberations about how officials should address serious adverse events in clinical trials.
Representative photo: NCI/Unsplash.
Health11/Dec/2020
Bengaluru: In November, two leading Indian COVID-19 vaccine manufacturers, Bharat Biotech and Serum Institute of India (SII), found themselves embroiled in controversy. Media reports alleged that there had been a “serious adverse event” in phase 1 of Bharat Biotech’s clinical trials for Covaxin. Phase 1 tests the safety of a new drug or vaccine in human subjects for the first time.
Then, a 40-year-old man in Chennai, through a legal notice to SII, sought compensation of Rs 5 crore for an illness he alleged appeared after he participated in a clinical trial for Covishield, SII-made version of University of Oxford and AstraZeneca’s COVID-19 vaccine candidate. ....

United Kingdom , South Africa , West Bengal , Tamil Nadu , Mira Desai , Karolina Grabowska Pexels , T Jacob John , Santanu Tripathi , Rajesh Bhushan , University Of Oxford , Indian Council Of Medical Research , Calcutta School Of Tropical Medicine , Research Centre , Nootan Medical College , Central Drugs Standard Control Organisation , Sri Ramachandra Institute , Christian Medical College , Mangaluru Yenepoya University , Sri Ramachandra Institute Of Higher Education , Serum Institute Of India , Expert Committee , Bharat Biotech , Serum Institute , Calcutta School , Tropical Medicine , Anil Vij ,